GlassScriptPhysician profile
Steven Wayne Croley
NPI 1265559272
$150,701.37
in general payments reported to CMS, 2019-2025
22 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $16K · 2021: $25K · 2022: $18K · 2023: $15K · 2024: $21K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $34K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $12K · Food and Beverage: $3,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $34,200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,800.00 |
| Travel and Lodging | $11,601.12 |
| Food and Beverage | $3,224.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $106,238.98 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $36,343.50 | 2019-2024 | Jornay Pm |
| Allergan, INC. | $5,870.55 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $535.18 | 2019-2024 | Invega Sustenna |
| Corium, LLC | $309.76 | 2021-2025 | Azstarys |
| Tris Pharma INC | $248.93 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $236.14 | 2019-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $219.68 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $107.69 | 2019-2020 | |
| Neuronetics, INC. | $94.90 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $88.28 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $86.21 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $72.96 | 2019-2020 | |
| Lundbeck LLC | $60.71 | 2019-2020 | |
| Bausch Health US, LLC | $38.73 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $33.91 | 2019 | |
| Vertical Pharmaceuticals, LLC | $28.28 | 2019-2025 | Relexxii |
| Abbvie INC. | $24.21 | 2021 | |
| Lilly USA, LLC | $17.99 | 2023 | Mounjaro |
| Indivior INC. | $16.02 | 2020 | |
| Rhodes Pharmaceuticals L.P. | $15.13 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.63 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Croley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.